The Shareholders Foundation announced that a deadline is coming up on January 9, 2017 in the lawsuit filed for certain investors in NASDAQ:DNAI shares over alleged securities laws violations by ProNAi Therapeutics Inc.
Investors who purchased shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) have certain options and there are strict and short deadlines running. Deadline: January 9, 2017. NASDAQ:DNAI stockholders should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The plaintiff alleges on behalf of certain purchasers of ProNAi Therapeutics Inc (NASDAQ:DNAI) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that ProNAi Therapeutics Inc made allegedly materially false and misleading statements about the potential and efficacy of its drug product candidate PNT2258 in the company’s public filings, which caused ProNAi’s stock price to be artificially inflated between July 15, 2015 and June 6, 2016, thus harming investors.
On June 6, 2016, ProNAi Therapeutics Inc (NASDAQ:DNAI announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ProNAi Therapeutics Inc’s President and CEO Nick Glover said, “Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine,” the Company has “decided to suspend the development of PNT2258” because the results were not “robust enough to justify continued development of the drug in DLBCL.” Shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) declined from $6.70 per share on June 2, 2016, to $1.98 per share on June 10, 2016.
Those who purchased NASDAQ:DNAI shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego